logo

VERA

Vera Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.36 / 10
Netural

Fundamental analysis of Vera Therapeutics indicates a below-average status (3.4/10). Key concerns include a low Net profit / Total profit ratio of 100.0% (score 0) and a negative Revenue-MV value of -0.2574 (group 2, score 1/3), which offset stronger Asset-MV (score 2) and Profit-MV (score 2) factors. The PB-ROE factor stands at 2.5306, placing it in group 4 with a quality score of 2/3. Overall, the fundamental picture is guarded, suggesting limited upside without improvement in profitability and revenue growth.

Fundamental(3.36)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight9.46%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.31%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.73%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight14.16%
1M Return7.79%
PB-ROE
Value2.53
Score2/3
Weight19.88%
1M Return10.68%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.66%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.21%
1M Return0.86%
Asset-MV
Value-0.50
Score2/3
Weight32.30%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight14.18%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.42%
1M Return-0.30%
Is VERA fundamentally strong?
  • VERA scores 3.36/10 on fundamentals and holds a Fair valuation at present. Backed by its -42.73% ROE, 0.00% net margin, -13.96 P/E ratio, 7.64 P/B ratio, and -52.87% earnings growth, these metrics solidify its Netural investment rating.